Group Leader of the Genetics Unit – Institute for Diabetes and Obesity
Dr. Alberto Cebrian Serrano
Alberto Cebrian-Serrano works at the intersection of genetics, metabolism, and molecular biology to improve our understanding of metabolic disorders and develop ways to improve human health through bioengineering.
Academic Pathway
At the Institute of Diabetes and Obesity, Alberto Cebrian-Serrano’s expertise involves applying and developing CRISPR tools to model and treat diseases, including metabolic syndrome, obesity and diabetes. His research group focuses on genetically modified mouse models using DNA CRISPR targeting and also CRISPR-mediated activation technology to turn on silenced genes and mobilize endogenous defences against metabolic dysfunction. Specifically, his laboratory studies the conditional regulation of CRISPR activation, allowing for robust spatiotemporal control of endogenous gene expression whilst minimising genotoxicity and off-target effects. The mastery and further development of these genetic engineering tools are critical for bridging basic research with applied research.
Alberto Cebrian-Serrano joined Helmholtz Zentrum in 2017. Before moving to Munich, he launched is first steps with genome engineering as postdoctoral researcher at the Oxford University from 2015 to 2017 and at the Oldenburg University from 2013 to 2015. He received his PhD from the Technical University of Valencia and his Bachelor in Veterinary Medicine from the Autonomous University of Barcelona.
Expertise
Genetics
CRISPR/Cas9 Genome editing
CRISPR-mediated activation